Post-operative analgesia for day-case ankle arthroscopy

Post-operative analgesia for day-case ankle arthroscopy: comparison of intra-articular racemic (RS)-bupivacaine with S(-)-bupivacaine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11419005

Enrollment

Registered

2010-05-28

Start date

2008-04-29

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Generic Health Relevance and Cross Cutting Themes

Interventions

Post-operative, single injection of 20 ml of 0.5% S(-)-bupivicaine or 20 ml 0.5% racemic (RS)-bupivicaine into the ankle joint.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18 years and above undergoing day case ankle arthroscopy who have given informed written consent

Exclusion criteria

Exclusion criteria: 1. Allergy or intolerance to any drugs used in the study 2. Spinal or epidural anaesthesia 3. Pregnancy

Design outcomes

Primary

Measure	Time frame
The analgesic effect of treatments: 1. Time to first supplemental analgesia following discharge from recovery 2. Visual Analogue Scale (VAS) at 30 mins, 1 hour	—

Secondary

Measure	Time frame
1. Differences in VAS scores between intra-articular chirocaine and marcain in the first 24 hours 2. Investigate whether intra-articular chirocaine reduces supplemental analgesia requirements in comparison to marcain in the first 24 hours	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026